方法：回顾性研究。纳入79例79眼不同类型视网膜静脉阻塞伴黄斑水肿患者[视网膜分支静脉阻塞(BRVO)54眼，非缺血型视网膜中央静脉阻塞(non-iCRVO)16眼，缺血型视网膜中央静脉阻塞(iCRVO)9眼]，采用3+PRN方案治疗，随访6mo，记录基线、治疗后1d，1、2、3、4、5、6mo的最佳矫正视力(BCVA，LogMAR)、黄斑中心凹视网膜厚度(CMT)等变化。

结果：三种不同类型RVO治疗后6mo BCVA均较基线提高(0.22±0.23 vs 0.70±0.32； 0.24±0.19 vs 0.73±0.27； 1.20±0.37 vs 1.92±0.23； 均P<0.05)，OCT显示黄斑CMT明显降低(199±27 vs 422±162μm； 195±16 vs 550±158μm； 231±55 vs 583±152μm； 均P<0.05)。三种不同类型RVO在不同就诊时间组内治疗后各时间CMT均较基线下降(P<0.05)，不同就诊时间组间CMT均无差异(P>0.05)。BRVO、non-iCRVO患者在不同就诊时间组内治疗后BCVA均较基线改善(P<0.05)，iCRVO患者>90d组视力几乎无提升。

结论：玻璃体腔内注射康柏西普可以有效治疗RVO引起的黄斑水肿。对于RVO患者，早期及时的进行抗血管内皮生长因子(VEGF)治疗，有助于其远期视力的提高并维持稳定； 延迟抗VEGF药物治疗可能会降低其视力提升的空间。

METHODS: Retrospective cohort study of 79 patients 79 eyes in different types of RVO(BRVO:54; non-ischemic CRVO: 16; ischemic CRVO: 9)received intravitreal injection of conbercept. After 3mo injection of conbercept(IVIC), a pro re nata(PRN)strategy was adopted. The best-corrected visual acuity(BCVA,LogMAR)and central macular thickness(CMT)were recorded at baseline and at 1d, 1, 2, 3, 4, 5, 6mo post-treatment.

RESULTS: At 6mo, in different types of RVO, the BCVA were improved significantly than baseline(0.22±0.23 vs 0.70±0.32; 0.24±0.19 vs 0.73±0.27; 1.20±0.37 vs 1.92±0.23; all P<0.05). CMT were decreased significantly than baseline(199±27 vs 422±162μm; 195±16 vs 550±158μm; 231±55 vs 583±152μm; all P<0.05). In three different treatment time groups, CMT in different types of RVO were decresed than the baselineat different time points after treatment(P<0.05), and there was no difference between groups(P>0.05). In three different treatment time groups, BCVA in BRVO and non-iCRVO were improved than the baseline in three groups(P<0.05), but in iCRVO there were little improved in >90d group.

CONCLUSION: Intravitreal injection of conbercept can effectively treat macular edema caused by RVO. Early and timely treatment of anti-VEGF may help improve and maintain the stability of long-term vision, and delayed anti-VEGF treatment may reduce the space for the improving vision.